Ever Supreme Bio Technology Co (6712) Fair Value & Analysis
Healthcare · TW · Market cap 13.9B TWD
Fair value as of: Jun 24, 2026
Analysis
Ever Supreme Bio Technology Co (6712) currently trades at 141.50 TWD, while our model-based Fair Value estimate is 62.28 TWD — implying the stock looks roughly 56.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; chimeric antigen receptor immune cells, a chimeric antigen receptor immune cells product; and allogeneic bone-marrow stem cells, used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. In addition, the company develops allogeneic umbilical cord mesenchymal stem cells (UMSC01), used to treat cardiovascular diseases and strokes. Further, it engages in the sale of other health products…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Ever Supreme Bio Technology Co (6712) undervalued?
What is the fair value of 6712?
What is the quality score of 6712?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.